Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 1

Status

Completed 2Unknown 1

Sponsor Class

NIH 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Thoracic 177Head & Neck 27Gastrointestinal 27Breast 24CNS 21Genitourinary 18Sarcoma 11Other solid neoplasm 8Tumor-Agnostic 6Gynecologic 6Endocrine 4Dermatologic 3Other hematologic neoplasm 1Lymphoid 1

Conditions

Skin Neoplasms 3

Interventions

pembrolizumab 326Nivolumab 289Ipilimumab 260Cyclophosphamide 193aldesleukin 145Interleukin-2 109fludarabine phosphate 106Temozolomide 83Dacarbazine 81fludarabine 80Radiotherapy 74trametinib 73Vemurafenib 69dabrafenib 66Biopsy 65sargramostim 50Bevacizumab 50Radiosurgery 49Paclitaxel 49Peripheral Blood Stem Cell Transplantation 48Carboplatin 48Magnetic Resonance Spectroscopy 47Imiquimod 47Aminolevulinic Acid 47binimetinib 45Cisplatin 45CTLA-4 Antigen 43cemiplimab 42atezolizumab 41Specimen Handling 40

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Interventional × Gefitinib × Dermatologic × Clear all
NCT00126555 2019-08-30

Gefitinib in Treating Patients Who Are Undergoing Surgery and/or Radiation Therapy for Locally Advanced or Recurrent Squamous Cell Skin Cancer

National Cancer Institute (NCI)

Phase 2 Completed
23 enrolled 12 charts
Dermatologic

Skin Neoplasms

NCT00054691 2015-03-13

ZD1839 (Iressa) for Recurrent or Metastatic Squamous Cell Carcinoma of the Skin

M.D. Anderson Cancer Center

Phase 2 Completed
40 enrolled 6 charts
Dermatologic

Skin Neoplasms

NCT00423397 2013-12-19

Gefitinib and PEG-Interferon Alfa-2a in Treating Patients With Unresectable or Metastatic Skin Cancer

National Cancer Institute (NCI)

Phase 1/2 Unknown
16 enrolled
Dermatologic

Skin Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡